Blab Business
Morepen Laboratories Shares Hit 52-Week High After Early-Completion of Capacity Expansion
Morepen Laboratories Ltd. (NSE: MOREPENLAB) surged to a 52‑week high on Monday, as the company announced that the first phase of its manufacturing‑capacity expansion finished ahead of schedule. The stock opened at ₹113.74 and climbed 7.4 % to ₹122.14 before settling at ₹120.32 by 12:15 p.m., a peak that marked the highest level the shares have reached in a year.
The rally was part of a broader uptrend that has seen the share price rise 17 % over the last four trading sessions. A total of 15.85 million shares changed hands on the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE) during the day, underscoring the market’s appetite for Morepen’s recent developments.
Morepen, a small‑cap pharmaceutical company listed on both the NSE and BSE, has been steadily expanding its contract‑development and manufacturing (CDMO) and active‑pharmaceutical‑ingredient (API) capabilities. The company’s installed reactor capacity grew from 535 kL to 614 kL, surpassing the 600 kL target that had been set for the second quarter of FY27. Completing the expansion earlier than previously indicated, Morepen now has the capacity to scale commercial CDMO supplies and strengthen its existing API business.
Financially, the company reported a 394 % year‑on‑year rise in profit after tax (PAT) to ₹56.35 crore for the first quarter of FY27 (Q1FY27). Revenue also grew 34 % YoY to ₹575.31 crore, up from ₹429.64 crore in the same quarter of the previous fiscal year. Earnings before interest, tax, depreciation and amortisation (EBITDA) jumped 207 % YoY to ₹87.72 crore, with the margin improving to 15.25 % from 6.65 % a year earlier. These results reflect better operating leverage and stronger performance in the API segment.
The market reaction to the capacity‑expansion announcement underscores investor confidence in Morepen’s growth strategy. While the share price remains well below its all‑time high of ₹234 reached in March 2000, it has rallied 192 % in 2026 and 50 % in the last month alone. Analysts note that the early completion of the first expansion phase could accelerate the company’s ability to secure larger CDMO contracts, potentially boosting future revenue streams.
Morepen’s board is scheduled to meet on 22 May 2026 to approve Q4 and FY2026 results, according to a notice filed with the exchanges. The company’s recent performance and the capacity expansion are likely to be key discussion points. Investors will also be watching the company’s next earnings release, expected in the coming months, for indications of how the expanded capacity translates into commercial output.
In summary, Morepen Laboratories’ shares reached a 52‑week high following the early completion of its first capacity‑expansion phase, which increased reactor capacity to 614 kL. The company’s Q1FY27 results showed significant gains in PAT, revenue, and EBITDA, reflecting improved operating leverage and API performance. The stock’s recent rally, combined with the expansion milestone, positions Morepen for potential growth in its CDMO and API businesses, while investors await further updates from the upcoming board meeting and subsequent earnings reports.
The rally was part of a broader uptrend that has seen the share price rise 17 % over the last four trading sessions. A total of 15.85 million shares changed hands on the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE) during the day, underscoring the market’s appetite for Morepen’s recent developments.
Morepen, a small‑cap pharmaceutical company listed on both the NSE and BSE, has been steadily expanding its contract‑development and manufacturing (CDMO) and active‑pharmaceutical‑ingredient (API) capabilities. The company’s installed reactor capacity grew from 535 kL to 614 kL, surpassing the 600 kL target that had been set for the second quarter of FY27. Completing the expansion earlier than previously indicated, Morepen now has the capacity to scale commercial CDMO supplies and strengthen its existing API business.
Financially, the company reported a 394 % year‑on‑year rise in profit after tax (PAT) to ₹56.35 crore for the first quarter of FY27 (Q1FY27). Revenue also grew 34 % YoY to ₹575.31 crore, up from ₹429.64 crore in the same quarter of the previous fiscal year. Earnings before interest, tax, depreciation and amortisation (EBITDA) jumped 207 % YoY to ₹87.72 crore, with the margin improving to 15.25 % from 6.65 % a year earlier. These results reflect better operating leverage and stronger performance in the API segment.
The market reaction to the capacity‑expansion announcement underscores investor confidence in Morepen’s growth strategy. While the share price remains well below its all‑time high of ₹234 reached in March 2000, it has rallied 192 % in 2026 and 50 % in the last month alone. Analysts note that the early completion of the first expansion phase could accelerate the company’s ability to secure larger CDMO contracts, potentially boosting future revenue streams.
Morepen’s board is scheduled to meet on 22 May 2026 to approve Q4 and FY2026 results, according to a notice filed with the exchanges. The company’s recent performance and the capacity expansion are likely to be key discussion points. Investors will also be watching the company’s next earnings release, expected in the coming months, for indications of how the expanded capacity translates into commercial output.
In summary, Morepen Laboratories’ shares reached a 52‑week high following the early completion of its first capacity‑expansion phase, which increased reactor capacity to 614 kL. The company’s Q1FY27 results showed significant gains in PAT, revenue, and EBITDA, reflecting improved operating leverage and API performance. The stock’s recent rally, combined with the expansion milestone, positions Morepen for potential growth in its CDMO and API businesses, while investors await further updates from the upcoming board meeting and subsequent earnings reports.
